

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 May 2019 (31.05.2019)



(10) International Publication Number
WO 2019/104134 A1

(51) International Patent Classification:
C07D 215/36 (2006.01) *A61K 31/4709* (2006.01)
A61P 7/06 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2018/062197

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:
21 November 2018 (21.11.2018)

(25) Filing Language: English

Published:

- with international search report (Art. 21(3))

(26) Publication Language: English

(30) Priority Data:
62/589,822 22 November 2017 (22.11.2017) US
62/691,709 29 June 2018 (29.06.2018) US

(71) Applicant: AGIOS PHARMACEUTICALS, INC.
[US/US]; 88 Sidney Street, Cambridge, MA 02139 (US).


(72) Inventors: SIZEMORE, Jacob, P.; 8 Vista Drive, Shrewsbury, MA 01545 (US). GUO, Liting; Qinshui Langting Blvd. 18, 2 HongFan Road, Suzhou, Jiangsu, 215000 (CN). MIRMEHRABI, Mahmoud; 36 Roxbury Crescent, Halifax, Nova Scotia, B3M 4T1 (CA). SU, Yeqing; 2225 Monastery Lane, Apt 310, Halifax, Nova Scotia, B3L 4R1 (CA).

(74) Agent: DAVIS, Steven, G. et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE



(57) Abstract: Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.

WO 2019/104134 A1